A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia

Purpose: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a variable clinical course. Several parameters have prognostic capabilities but are associated with altered response to therapy in only a small subset of patients. Experimental Design: We used gene expression profiling methods to generate predictors of therapy response and prognosis. Genomic signatures that reflect progressive disease and responses to chemotherapy or chemoimmunotherapy were created using cancer cell lines and patient leukemia cell samples. We validated and applied these three signatures to independent clinical data from four cohorts, representing a total of 301 CLL patients. Results: A genomic signature of prognosis created from patient leukemic cell gene expression data coupled with clinical parameters significantly differentiated patients with stable disease from those with progressive disease in the training data set. The progression signature was validated in two independent data sets, showing a capacity to accurately identify patients at risk for progressive disease. In addition, genomic signatures that predict response to chlorambucil or pentostatin, cyclophosphamide, and rituximab were generated and could accurately distinguish responding and nonresponding CLL patients. Conclusions: Thus, microarray analysis of CLL lymphocytes can be used to refine prognosis and predict response to different therapies. These results have implications for standard and investigational therapeutics in CLL patients. (Clin Cancer Res 2009;15(22):694755)

[1]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[2]  T. Möröy,et al.  Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. , 2003, Blood.

[3]  M. Hallek,et al.  Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.

[4]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[5]  Kim-Anh Do,et al.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. , 2007, Blood.

[6]  J. Roliński,et al.  Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. , 2008, Leukemia research.

[7]  M. West,et al.  Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[9]  David Botstein,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[10]  Lisa L. Smith,et al.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.

[11]  M. Caligiuri,et al.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Zhan,et al.  The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. , 2003, Leukemia research.

[13]  M Vihinen,et al.  Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion , 2001, Leukemia.

[14]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[15]  T. Shanafelt,et al.  Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. , 2007, Mayo Clinic proceedings.

[16]  H. Dressman,et al.  Genomic signatures to guide the use of chemotherapeutics , 2006, Nature Medicine.

[17]  Yuhai Tu,et al.  Identification of a global gene expression signature of B-chronic lymphocytic leukemia. , 2003, Molecular cancer research : MCR.

[18]  Lynette M. Smith,et al.  Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia , 2005, British journal of haematology.

[19]  K. Do,et al.  Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Gahrton,et al.  Identification of progression markers in B-CLL by gene expression profiling. , 2005, Experimental hematology.

[21]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[22]  M. Piris,et al.  Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation , 2007, Leukemia.

[23]  A. Ferrer,et al.  Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia. , 2004, Cancer genetics and cytogenetics.

[24]  B. Villoutreix,et al.  3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. , 2002, Blood.

[25]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[26]  R. Abseher,et al.  Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Z. Estrov,et al.  The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. , 2002, Blood.

[28]  C. Rehder,et al.  Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia , 2007, American journal of hematology.

[29]  Z. Estrov,et al.  The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia , 2002 .

[30]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[32]  Steven L. Allen,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[33]  L. Klein-Hitpass,et al.  Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status , 2006, Leukemia.

[34]  C Stratowa,et al.  CDNA microarray gene expression analysis of B‐cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking , 2001, International journal of cancer.

[35]  S. Mukherjee,et al.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. , 2006, The New England journal of medicine.

[36]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[37]  John C Reed,et al.  Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.